Find uplifting stories about heroes, innovations, and solutions
79 results for "psychedelics"
A new AI platform called Lucy is solving a critical shortage in psychedelic therapy by training facilitators using real-world data from thousands of support calls. Built from a database of actual psychedelic experiences, Lucy helps prepare therapists for the emotional challenges of guiding patients through breakthrough mental health treatments.
A Tibetan lama with 54,000 hours of meditation experience showed identical brain patterns during deep meditation and a low dose of psychedelics. The discovery could help scientists understand consciousness and make meditation benefits more accessible.
Three psychedelic treatments for depression and PTSD could receive FDA approval as soon as this summer, potentially offering hope to millions struggling with mental health conditions. The accelerated review process cuts approval time from a year down to just weeks.
A new executive order cuts red tape for scientists studying psychedelic compounds like MDMA and psilocybin as treatments for depression, PTSD, and addiction. The breakthrough also includes $50 million for research into ibogaine, a powerful substance showing promise for opioid addiction.
Researchers analyzed over 500 brain scans and discovered a common "neural fingerprint" across LSD, psilocybin, and three other psychedelics. This breakthrough could strengthen clinical trials testing these substances for depression and PTSD.
President Trump signed an executive order to expand access to psychedelic therapies for conditions like PTSD, depression, and addiction. The move signals growing mainstream acceptance of treatments once considered fringe medicine.
President Trump signed an executive order to accelerate research into psychedelic drugs for mental health treatment, directing $50 million to state programs. Veterans and advocacy groups hope the move could unlock new treatments for PTSD and depression.
The FDA is accelerating reviews of three psychedelic medications for depression and PTSD, moving promising mental health treatments closer to patients who desperately need them. Millions struggling with treatment-resistant conditions could soon have groundbreaking new options.
President Trump signed an order in April to speed up research into psychedelic treatments for mental health conditions, offering new hope for veterans and others struggling with depression and PTSD. Scientists are cautiously optimistic about the medical potential while carefully studying safety.
President Trump will sign an executive order Saturday to advance research into psychedelics like psilocybin and ibogaine for therapeutic use. The move could open doors for controlled access to these promising mental health treatments.
Researchers engineered a single tobacco plant to produce five therapeutic psychedelic compounds, creating a sustainable alternative to harvesting endangered toads and mushrooms. This biological factory could revolutionize mental health treatment access.
President Trump signed an executive order directing the FDA to expedite review of psychedelic drugs showing promise for veterans suffering from PTSD, depression, and traumatic brain injuries. One treatment already shows an 80-90% reduction in symptoms within one month.
Over 60% of U.S. voters now strongly support making psychedelics easier to study for medical use, a 14-point jump from 2023. The shift reflects growing public curiosity about therapeutic benefits of substances like psilocybin and MDMA.
A groundbreaking trial shows military veterans experiencing dramatic improvements in PTSD symptoms after just one session with ibogaine, a powerful natural psychedelic. The research could open new doors for millions struggling with treatment-resistant trauma.
New research shows psychedelics like psilocybin and MDMA could help people with PTSD recover in hours instead of months by actually rewiring trauma-affected brain systems. Clinical trials reveal 67% of patients no longer met PTSD criteria after MDMA-assisted therapy, offering hope to 12 million Americans struggling with the condition.
President Trump signed an executive order to speed up research and potential FDA approval of psychedelic therapies for veterans suffering from PTSD, depression, and addiction. While the move brings hope to those who've exhausted traditional treatments, experts emphasize these therapies still need rigorous testing in controlled settings.
A new executive order accelerates research into psychedelic medicines for mental illness, prioritizing veterans facing treatment-resistant PTSD and depression. The move ends decades of federal prohibition and could offer hope to the 17 veterans who die by suicide every day.
Scientists analyzed over 500 brain scans and discovered that five different psychedelic drugs create remarkably similar patterns of brain activity. This breakthrough could speed up the development of new mental health treatments for depression, anxiety, and addiction.
A sweeping executive order is accelerating psychedelic research for mental health treatment, unlocking funding and pathways that researchers have sought for years. The question now: Can scientists deliver on the promise fast enough to help those in crisis?
The FDA is accelerating breakthrough psychedelic therapies for treatment-resistant depression, PTSD, and alcohol use disorder after a presidential directive. Veterans and millions struggling with serious mental illness could gain access to promising new options backed by rigorous science.
Showing 20 of 79